Background: TIM-3 (T-cell immunoglobulin and mucin-domain containing-3) is an immune checkpoint protein involved in negatively regulating immune responses. TIM-3 can be expressed on T cells including regulatory T cells, NK cells, monocytes and macrophages. In cancer, TIM-3 has been identified on tumor-infiltrating lymphocytes making TIM-3 an attractive target for reversing the immune suppression that is characteristic of the tumor microenvironment. Outside of cancer, TIM-3 contributes to T cell exhaustion that occurs from chronic viral infections and importantly helps mediate maternal-fetal tolerance.

Validation: Each lot of conjugated antibody is quality control tested by staining tissue following the MIBI Staining Protocol optimized for the applicable tissue format with subsequent MIBIscope analysis using the appropriate positive and negative tissue field of views.

Recommended Usage: Human FFPE: 1 ug/mL dilution.
For optimal results, the antibody should be titrated for each desired application.

MIBI technology: Learn more about MIBI™ Technology, a multiplex IHC technology with unmatched sensitivity and true subcellular resolution.

References

• Das, M., Zhu, C., Kuchroo, V.K. Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev. 2017; 276(1):97-111.
• Li, Y. et al. Tim-3 signaling in peripheral NK cells promotes maternal-fetal immune tolerance and alleviates pregnancy loss. Sci Signal. 2017; 10, eaah4323.

* Conjugate tested on human tissue.